Use of insulin glargine in Japanese patients with type 1 diabetes.

OBJECTIVE To evaluate the results of treatment with an insulin glargine-based regimen as compared with those of an NPH insulin-based regimen. METHODS We reviewed the charts of 83 Japanese patients with Type 1 diabetes treated with insulin glargine for 12 months. PATIENTS Median age, 56.9 years (range, 24.6-74.8 years), mean (+/-S.D.) body mass index, 21.2 (+/-2.2) kg/m2. RESULTS The average HbA1c level of the cohort was 7.8 +/- 1.2% at baseline and 7.7 +/- 1.0% at the end of the 12-month treatment (P=0.34). The average insulin requirement per day in the cohort remained unchanged after the 12-month treatment (35.0 +/- 11.6 units/day versus 35.2 +/- 11.2 units/day (P=0.58). Of the 36 patients who were receiving twice or three times daily injections of NPH insulin, 30 could be switched to a single-daily injection of insulin glargine. The frequency of severe hypoglycemia with unconsciousness became lower after switching to the insulin glargine-based regimen than during treatment with the NPH-based regimen. The average ratio of the daily usage of insulin glargine to that of total insulin after 12 months was smaller than that reported from other countries (0.34 +/- 0.09). CONCLUSION These results obtained from a larger number of patients as compared to previous Japanese studies confirm earlier reports that insulin glargine provides equivalent glycemic control to human NPH insulin, with a lower incidence of severe hypoglycemia. Thus, treatment with insulin glargine provides some benefits to Japanese patients with Type 1 diabetes.

[1]  S. Ashwell,et al.  Twice‐daily compared with once‐daily insulin glargine in people with Type 1 diabetes using meal‐time insulin aspart , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[2]  R. Becker,et al.  Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. , 2006, Diabetes technology & therapeutics.

[3]  S. Madsbad,et al.  A low‐fat diet improves peripheral insulin sensitivity in patients with Type 1 diabetes , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[4]  S. Ashwell,et al.  Optimal timing of injection of once‐daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal‐times , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[5]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[6]  T. Maruyama,et al.  Effect of switching from NPH insulin to insulin glargine on glycemic control in Japanese type 1 diabetic patients , 2005 .

[7]  J. V. Nielsen,et al.  A Low Carbohydrate Diet in Type 1 Diabetes , 2005, Upsala journal of medical sciences.

[8]  P. Brunetti,et al.  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. , 2000, Diabetes.

[9]  P. Raskin,et al.  A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. , 2000, Diabetes care.

[10]  I. Hirsch,et al.  Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. , 2000, Diabetes care.

[11]  T. Pieber,et al.  Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. , 2000, Diabetes care.

[12]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.